ArticleCancer medicine2019
Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Global burden of multiple myeloma(1990-2021) and projections up to 2035: a methodical analysis leveraging the global burden of disease 2021 study and Mendelian randomization.Journal of the Egyptian National Cancer Institute · 2026Article
- China data on the burden of alcohol-associated liver cancer from 1990 to 2021: a systematic analysis from the global burden of disease study 2021.Ecancermedicalscience · 2026Article
- Changes in peripheral blood B cell levels predict overall survival in patients with advanced liver cancer treated with immune target inhibitors.Discover oncology · 2025Article
- Trends and projections of the global burden of pulmonary arterial hypertension (1990-2050): An observational trend study.Medicine · 2025Observational
- Temporal trend and attributable risk factors of ischemic stroke burden in China, 1990-2021.BMC neurology · 2025Article
- Age-Period-Cohort Analysis on the Burden of Gastrointestinal Cancers in China: Trends, Risk Factors, and Predictions.Healthcare (Basel, Switzerland) · 2025Article
- Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Global burden of disease among adolescents and young adults with drug use disorders, 1990-2021: based on GBD 2021.Frontiers in public health · 2025Article
- Article
- Burden, trends and projections of liver cancer in China and G20 countries: a comparative study based on the global burden of disease database 2021.Frontiers in public health · 2025Observational
- Combining serum biomarkers and MRI radiomics to predict treatment outcome after thermal ablation in hepatocellular carcinoma.American journal of translational research · 2025Article
- Case Report: Laparoscopic resection of a tumor in the right posterior lobe of the liver in a patient with situs inversus totalis.Frontiers in oncology · 2025Article
- Burden of drug use disorders in the United States from 1990 to 2021 and its projection until 2035: results from the GBD study.BMC public health · 2024Article
- Mortality Burden of Liver Cancer in China: An Observational Study From 2008 to 2020.Journal of clinical and translational hepatology · 2024Article
- Trends in Mortality of Cirrhosis in China: An Analysis of the China Death Surveillance Database from 2008 to 2020.Journal of clinical and translational hepatology · 2024Article
- Analysis of study Global Burden of Disease in 2021: global, regional, and national burden of nutritional deficiency from 1990 to 2021.Frontiers in nutrition · 2024Article
- Global burden of drug use disorders by region and country, 1990-2021.Frontiers in public health · 2024Article
- Trends in liver cancer mortality in China from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019.BMJ open · 2023Article
- Analysis and prediction of the efficacy and influencing factors of camrelizumab combined with TACE and sorafenib in the treatment of advanced hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Trends of Mortality in End-Stage Liver Disease - China, 2008-2020.China CDC weekly · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLiver cancer is a commonly diagnosed malignancy in China. The etiologies of liver cancer are widely known, although studies on temporal trends in liver cancer caused by specific etiologies are rare.
methodsData on the incidence and mortality of liver cancer were retrieved from the Global Burden of Diseases Study 2017. The estimated annual percentage change (EAPC) was used to quantify temporal trends in the age-standardized incidence rate (ASIR) and the age-standardized mortality rate (ASMR) of liver cancer from 1990 to 2017.
resultsNationwide, the number of incident cases of liver cancer increased from 258 000 in 1990 to 515 900 in 2017. The ASIR decreased from 27.16 per 100 000 to 26.04 per 100 000 during this period, with an EAPC of -0.64 (95% confidence interval [CI] -0.84, -0.44). The number of deaths increased from 245 300 in 1990 to 418 200 in 2017, and the ASMR decreased from 26.72 to 21.30 (EAPC = -1.16, 95% CI -1.35, -0.97). The most pronounced decreases in the ASIR and ASMR were observed in liver cancer due to hepatitis B and in people aged 15-49 years.
conclusionsSince the extensive efforts for prevention of hepatitis B virus infection, the incidence of liver cancer due to hepatitis B has significantly decreased. However, liver cancer due to hepatitis C, NASH, and other causes remains a major public health concern. Additional preventive strategies tailored to liver cancer are needed to further reduce its disease burden in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.